PHARMA DEALS DURING JULY 2014

(Part 3 out of 3)

by Medius Asociates

This table lists all the major pharma collaborations, acquisitions and mergers agreed during July 2014

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Shire/  AbbVie	Company acquisition (tax inversion)	Product portfolio - neuroscience, rare diseases, gastrointestinal, internal medicine	54,000
Abbott/ Mylan	Asset acquisition (tax inversion)	Ex-US developed markets specialty and branded generics business *	5,300
Rottapharm/ Meda	Company acquisition	Portfolio of Rx and consumer products	3,080
Cosmo Technologies/ Salix Pharmaceuticals	Merger (tax inversion)	Portfolio of treatments for gastrointestinal disease and disorders	2,700
Almirall/ AstraZeneca	Asset acquisition	Respiratory business including various respiratory assets and device capabilities	2,095
Seragon Pharmaceuticals/ Genentech	Company acquisition	Selective Estrogen Receptor Degrader (SERD) platform for hormone dependent breast cancer, inc ARN-810 (p1)	1,725
Baxter Bioscience/ Pfizer	Asset acquisition	Vaccine business and production facilities	635
Zealand Pharma/ Boehringer Ingelheim	R&D collaboration	Peptide discovery collaboration with cardio-metabolic focus	395
InnoPharma/ Pfizer	Company acquisition	Portfolio of generic FDA approved products and injectable and ophthalmic products under development	360
Sigma-Tau/ Jazz Pharmaceuticals	Regaining rights **	Defibrotide for severe hepatic veno-occlusive disease (approved EU/ NDA US)	250
ArmaGen/ Shire	Licence, collaboration	AGT-182, enzyme replacement therapy for  Hunter syndrome (preclinical)	225
CureVac/ Sanofi Pasteur	Exercise of option,  licence	RNActive vaccine technology vs undisclosed pathogens (preclinical)	202+
Aciex Therapeutics/ NicOx	Company acquisition	Portfolio of ophthalmic products, inc AC-170  for allergic conjunctivitis (p3)	120
Anacor Pharmaceuticals/  PharmaDerm (Sandoz)	Licence†	Kerydin topical for toenail onychomycosis (approved)	110
AmorChem/ Roche	Discovery collaboration, option to license	Small molecule therapy for myotonic muscular dystrophy 1 (discovery)	107
UCB/ Dermira	Licence ††	Cimzia (certolizumab pegol) - drug repurposing (p2 for psoriasis)	89.5 + 20 equity
Codexis/ GSK	Licence	CodeEvolver protein engineering technology (platform)	63.5+
Supernus Pharmaceutical/  HealthCare Royalty Partners	Royalty/milestone monetisation	Certain royalty /milestone rights to Orenitram (treprostinil) extended-release tablets  (marketed)	30
Immunocore/ Eli Lilly	Co-discovery /co-development, options (cost/profit share)	ImmTAC (Immune mobilising mTCR Against Cancer) technology (discovery)	25+
Noven Therapeutics/  ANI Pharmaceuticals	Acquisition of NDA †	Lithobid (lithium carbonate extended release  tablets) for manic-depressive illness (NDA)	12

All deals are worldwide unless otherwise noted

*    Europe, Japan, Canada, Australia and New Zealand

**  US + all other countries in the Americas

†    US

††     Exclusive licence to develop for psoriasis in N. America, EU; licence to market N. America to dermatologists

Fuente: PMLiVE

Haciendo click en cada uno de los links siguientes, 

accederán a los Contenidos de nuestros 

TALLERES DE CAPACITACIÓN IN COMPANY A MEDIDA:

(translator on page)

Cómo INCORPORAR y APLICAR Modelos de
PENSAMIENTO ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_6246.html

Cómo GERENCIAR EFICAZMENTE a partir del

MANAGEMENT ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_3.html

Cómo GERENCIAR PROCESOS DE CAMBIO
y no sufrir en el intento

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa.html

¿Cómo IMPLEMENTAR ESTRATEGIAS EFECTIVAS?

Recetas para Escenarios Turbulentos

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-taller-de.html

Consultas al mail: msg.latam@gmail.com

ó al TE: +5411-3532-0510